• IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here.

    The OTHER forum is HERE so please stop asking.

New Gastric Cancer Treatments 2024

ginfreely

Alfrescian
Loyal
Joined
Nov 9, 2010
Messages
79,103
Points
113
TheSocialMedwork
Search


EN
Menu
Account


New Gastric Cancer Treatments 2024​


Gastric cancer, also known as stomach cancer, is a disease in which malignant (cancer) cells form in the lining of the stomach. This type of cancer can develop slowly over many years and often goes undetected because it rarely causes early symptoms. Risk factors for gastric cancer include a diet high in salty and smoked foods, a family history of the disease, smoking, and certain bacterial infections such as Helicobacter pylori. Symptoms may include indigestion, stomach discomfort, a bloated feeling after eating, mild nausea, and loss of appetite, but these can often be mistaken for common stomach ailments. Early detection is crucial, as the prognosis for gastric cancer is significantly better when diagnosed at an early stage.
Treatment options for gastric cancer depend on the stage of the disease, the location of the tumor, and the overall health of the patient. Surgery is the most common treatment for early-stage gastric cancer, aiming to remove the tumor and possibly some surrounding tissue. Chemotherapy may be used before surgery to shrink the tumor or after surgery to eliminate any remaining cancer cells. Targeted therapy drugs, which focus on specific abnormalities present within cancer cells, can also be effective in treating gastric cancer. It is important for patients to discuss with their healthcare team to understand the potential benefits and risks of each treatment option, as well as any possible side effects, to make an informed decision that aligns with their treatment goals and quality of life considerations.

Gastric-Cancer.png


https://everyone.org/explore/treatment/?id=10
 

Treatment options​


Treatment optionEstimated costEfficacyEligibility
SurgeryVaries widelyCan be curative for early-stage cancerLocalized gastric cancer, operable tumors
Chemotherapy$1,000 - $12,000Varies; adjuvant chemotherapy may improve survivalMost stages, often in combination with other treatments
Radiation Therapy$2,000 - $10,000Can improve local control of the diseaseOften used for locally advanced gastric cancer
Targeted Therapy (e.g., Trastuzumab)$4,000 - $10,000Effective in HER2-positive gastric cancerHER2-positive gastric cancer
Immunotherapy (e.g., Opdivo)$13,000 - $20,000Can be effective in PD-L1 positive tumorsAdvanced or metastatic PD-L1 positive tumors after chemotherapy
Immunotherapy (e.g., Keytruda)$10,000 - $15,000Effective in MSI-H or dMMR cancersUnresectable or metastatic, MSI-H or dMMR tumors
Angiogenesis Inhibitor (e.g., Cyramza)$6,000 - $12,000Can prolong survival in advanced gastric cancerAdvanced or metastatic gastric cancer after prior chemotherapy
Tyrosine Kinase Inhibitor (e.g., Qinlock)$18,000 - $22,000Effective in GIST after other treatments failAdvanced GIST with specific mutations
Antibody-Drug Conjugate (e.g., Enhertu)$13,000 - $18,000Effective in HER2-positive gastric cancerHER2-positive metastatic gastric cancer
Experimental (e.g., Jeselhy (pimitespib))Cost not establishedUnder investigationCurrently in clinical trials



 
Last edited:

Treatment options​


Treatment optionEstimated costEfficacyEligibility
SurgeryVaries widelyCan be curative for early-stage cancerLocalized gastric cancer, operable tumors
Chemotherapy$1,000 - $12,000Varies; adjuvant chemotherapy may improve survivalMost stages, often in combination with other treatments
Radiation Therapy$2,000 - $10,000Can improve local control of the diseaseOften used for locally advanced gastric cancer
Targeted Therapy (e.g., Trastuzumab)$4,000 - $10,000Effective in HER2-positive gastric cancerHER2-positive gastric cancer
Immunotherapy (e.g., Opdivo)$13,000 - $20,000Can be effective in PD-L1 positive tumorsAdvanced or metastatic PD-L1 positive tumors after chemotherapy
Immunotherapy (e.g., Keytruda)$10,000 - $15,000Effective in MSI-H or dMMR cancersUnresectable or metastatic, MSI-H or dMMR tumors
Angiogenesis Inhibitor (e.g., Cyramza)$6,000 - $12,000Can prolong survival in advanced gastric cancerAdvanced or metastatic gastric cancer after prior chemotherapy
Tyrosine Kinase Inhibitor (e.g., Qinlock)$18,000 - $22,000Effective in GIST after other treatments failAdvanced GIST with specific mutations
Antibody-Drug Conjugate (e.g., Enhertu)$13,000 - $18,000Effective in HER2-positive gastric cancerHER2-positive metastatic gastric cancer
Experimental (e.g., Jeselhy (pimitespib))Cost not establishedUnder investigationCurrently in clinical trials



Wow very good summary!
 

Treatments options in detail​

Standard Treatment Options for Gastric Cancer​

The treatment of gastric cancer typically depends on the stage of the disease, the patient's overall health, and their preferences. The most common treatments include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

Surgery​

Surgery is often the first line of treatment for gastric cancer, especially if diagnosed at an early stage. Procedures may include subtotal gastrectomy, where part of the stomach is removed, or total gastrectomy, where the entire stomach is removed. Lymph nodes around the stomach may also be removed to check for the spread of cancer.

Chemotherapy​

Chemotherapy uses drugs to destroy cancer cells and is commonly used before surgery (neoadjuvant chemotherapy) to shrink tumors, making them easier to remove, or after surgery (adjuvant chemotherapy) to kill any remaining cancer cells. Chemotherapy can also be used for advanced gastric cancer to relieve symptoms and extend life. Drugs such as fluorouracil, capecitabine, oxaliplatin, and cisplatin are commonly used.

Radiation Therapy​

Radiation therapy uses high-energy rays to kill cancer cells. It may be used before surgery to shrink tumors or after surgery to destroy any remaining cancer cells. It can also be combined with chemotherapy (chemoradiation).

Targeted Therapy​

Targeted therapy drugs act on specific molecular targets associated with cancer and can be used for advanced or metastatic gastric cancer. Trastuzumab is one such drug used for HER2-positive gastric cancer.

Immunotherapy​

Immunotherapy helps the body's immune system fight cancer. Pembrolizumab (Keytruda) is an immunotherapy drug approved for advanced gastric cancer with certain characteristics, such as high levels of PD-L1 expression or mismatch repair deficiency (dMMR).

Opdivo (Nivolumab)​

Opdivo is an immunotherapy drug approved for the treatment of advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in patients who have previously received two or more types of chemotherapy. It is a PD-1 inhibitor that helps the immune system recognize and attack cancer cells.

Keytruda (Pembrolizumab)​

Keytruda is another PD-1 inhibitor used in the treatment of PD-L1 positive advanced gastric or gastroesophageal junction cancer. It is usually given to patients who have already received other cancer treatments.

Cyramza (Ramucirumab)​

Cyramza is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist used as a single agent or in combination with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma after prior chemotherapy. It works by inhibiting the blood supply to tumors, which can slow their growth.

Qinlock (Ripretinib)​

Qinlock is a kinase inhibitor approved for the treatment of advanced gastrointestinal stromal tumors (GIST), a type of tumor that can occur in the stomach. It is used in patients who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Enhertu (Fam-trastuzumab deruxtecan-nxki)​

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate approved for the treatment of adult patients with unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Experimental and Off-Label Treatments​

Experimental treatments for gastric cancer are typically available through clinical trials. These may include new chemotherapy drugs, targeted therapies, immunotherapies, or combinations of existing treatments. Patients interested in experimental treatments should consult with their healthcare provider and consider enrolling in a clinical trial.

Off-label drug use involves prescribing drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration. Physicians may consider off-label use of medications based on their clinical judgment, published literature, and individual patient circumstances.

Jeselhy (Pimitespib)​

Jeselhy, also known as pimitespib, is an experimental heat shock protein 90 (HSP90) inhibitor currently being investigated in clinical trials for the treatment of gastric cancer. As an investigational drug, it is not approved by the FDA for any indication at this time.

Conclusion​

Treatment options for gastric cancer are diverse and can be tailored to the individual's disease characteristics and personal health. Standard treatments are the backbone of therapy, while drugs like Opdivo, Keytruda, Cyramza, Qinlock, and Enhertu represent newer advances in the field. Experimental treatments, such as Jeselhy, offer hope for future advancements but are not yet approved for general use. Patients should discuss all available treatment options, including experimental and off-label use, with their healthcare provider to determine the best course of action for their specific situation.
 
Last edited:

Treatment options​


Treatment optionEstimated costEfficacyEligibility
SurgeryVaries widelyCan be curative for early-stage cancerLocalized gastric cancer, operable tumors
Chemotherapy$1,000 - $12,000Varies; adjuvant chemotherapy may improve survivalMost stages, often in combination with other treatments
Radiation Therapy$2,000 - $10,000Can improve local control of the diseaseOften used for locally advanced gastric cancer
Targeted Therapy (e.g., Trastuzumab)$4,000 - $10,000Effective in HER2-positive gastric cancerHER2-positive gastric cancer
Immunotherapy (e.g., Opdivo)$13,000 - $20,000Can be effective in PD-L1 positive tumorsAdvanced or metastatic PD-L1 positive tumors after chemotherapy
Immunotherapy (e.g., Keytruda)$10,000 - $15,000Effective in MSI-H or dMMR cancersUnresectable or metastatic, MSI-H or dMMR tumors
Angiogenesis Inhibitor (e.g., Cyramza)$6,000 - $12,000Can prolong survival in advanced gastric cancerAdvanced or metastatic gastric cancer after prior chemotherapy
Tyrosine Kinase Inhibitor (e.g., Qinlock)$18,000 - $22,000Effective in GIST after other treatments failAdvanced GIST with specific mutations
Antibody-Drug Conjugate (e.g., Enhertu)$13,000 - $18,000Effective in HER2-positive gastric cancerHER2-positive metastatic gastric cancer
Experimental (e.g., Jeselhy (pimitespib))Cost not establishedUnder investigationCurrently in clinical trials



So the conclusion is if your stomach cancer is not HER2 positive, not PDL1 positive, not micro satellite instable MSI-H or mismatch repair deficiency d-MMR, not GIST, you have no immunotherapy or targeted therapy or inhibitor etc options.
 

Jeselhy (Pimitespib)​

Jeselhy, also known as pimitespib, is an experimental heat shock protein 90 (HSP90) inhibitor currently being investigated in clinical trials for the treatment of gastric cancer. As an investigational drug, it is not approved by the FDA for any indication at this time.
So this is also for stomach cancer that is GIST aka sarcoma and not the majority 90% stomach cancer that is adenocarcinoma.
 
Back
Top